Every claim has a paper trail.
A short index of the studies, certificates, and registrations behind both products. We update this page as new data lands — and we're explicit when something is preliminary or in progress.
Why this page exists.
A wellness claim without a source is marketing copy. We made this page so you can audit us — every mechanism mentioned on the product pages links back to a published paper, a COA, a manufacturer registration, or a patent filing here.
If you want a copy of a specific document we don't show inline — the full Microbac COA, the Korean MFDS registration paperwork, the patent filing — email us and we'll send it.
Request a document"Initial readouts are encouraging, but the study is in progress."
Honest characterization beats a confident-sounding overstatement. Where studies are preliminary or ongoing, this page says so.
Ice Plant — referenced literature.
D-pinitol & insulin signaling
Nutrients (2024), 17, 193. Reports D-pinitol's effect on PI3K / Akt / IRS-2 signaling in INS-1 pancreatic β-cells, with downstream support for healthy glucose tolerance.
Inositols and glucose homeostasis
Food & Function (2019). Discusses cyclitol-class compounds (D-pinitol, myo-inositol) and their insulin-sensitizing role in preclinical models.
Mesembryanthemum crystallinum phytochemistry
Profile of secondary metabolites: D-pinitol, β-carotene, polyphenols, ascorbate. Halophyte adaptation produces unusually high concentrations of bioactive osmolytes.
Korean cultivar program
6-generation cold-tolerant cultivar developed under Korean government R&D funding (2022–2024) in collaboration with KIST (Korea Institute of Science & Technology).
α-glucosidase inhibition
In-vitro enzyme-inhibition assays support the proposed mechanism for Ice Plant's effect on post-prandial glucose — slowing the breakdown of dietary starches at the brush border.
Ongoing 1,000-person observational study
A current observational study with type 1 and type 2 participants. Preliminary readouts are encouraging but the study is in progress; we will publish full results when complete.
Basilopet — referenced literature.
Patent KR 10-2024-0113355
Patent filing covering the spore-culture process for the proprietary Bacillus coagulans KCCM 11712 strain isolated from Korean rice straw.
Intestinal survival study
Chungnam National University Agricultural Science Institute (July 2023). Fecal-CFU testing demonstrated that ~20%+ of orally administered spores survive transit and reach the intestine — a 2-log retention from a 10⁹ CFU dose.
Bacteriocin activity
In-vitro inhibitory activity of cell-free supernatant against E. coli (including ESBL-producing strains), Listeria, S. aureus, and other pathogens of veterinary concern.
Feed inclusion study
Optimal-economic inclusion rate of 0.4% by total daily feed weight identified across a 0.2–0.6% test range — the basis for the 1 g/day stick dosing.
Safety panel — in progress
K-FDA hemolytic, antibiotic-resistance, cytotoxicity, and metabolic-safety testing per WHO/FAO probiotic-safety guidelines. B. coagulans as a species is GRAS-recognized by the U.S. FDA.
Microbac Laboratories COA #A5G1912
U.S. third-party analysis (Warrendale, PA, July 2025): heavy metals not detected; CP/EE/CF/Ash all under 1%; energy 3 kcal/g.
Where it's made, by whom, under what standard.
FSSC 22000 v6
Cert #24-F-1382, valid through August 2027. Agricultural Corporation Gagopa-Healing Food, Changwon-si, Korea — manufacturer for the Ice Plant tea line.
Korean MFDS & Feed Control Act
Both products are registered with Korea's MFDS. Basilopet is registered under the Korean Feed Control Act for pet food additive use.
U.S. FDA & GRAS
Food Facility Registration submitted for the manufacturing site. B. coagulans as a species is GRAS-recognized in the U.S. for supplemental use.
Email us — we'll send it.
COAs, manufacturer registrations, patent filings, lab reports. If we have it, you can have it — say which document you want and we'll forward it.
Email msrdinc@gmail.com